Atrial and Ventricular Single Chamber Leadless Pacemakers

Purple background image with a blue illustrated heart

The next evolution in leadless technology.

At Abbott, we adapt quickly to changes in the world around us, harnessing leading-edge science and technology to deliver the best possible solutions for some of the world’s most important health challenges. Medical devices, like the AVEIR™ AR Leadless Pacemaker and AVEIR™ VR Leadless Pacemaker, use the most advanced technologies to keep hearts beating more regularly. 

Watch the video below to learn more. 

Introducing the World's First Atrial Leadless Pacemaker1

The flexibility to tailor therapy has taken a leap forward. Until now, leadless pacing could only be done in the right ventricle, which meant a conventional pacemaker was the only option for many patients. Now, with the world’s first atrial leadless pacemaker, more patients can benefit from leadless pacing that eliminates the risk of lead- and pocket-related complications and offers no visible scarring or arm movement restriction.

Aveir VR pacemaker device

Indications for Single Chamber Leadless Pacing

Atrial Pacing for Patients with:

▪ Sinus node dysfunction and normal AV and intraventricular conduction systems


Ventricular Pacing for Patients with:

▪ Significant bradycardia and normal sinus rhythm with only rare episodes of AV block or sinus arrest
▪ Chronic atrial fibrillation

Aveir atrial pacing pacemaker
Aveir atrial pacing pacemaker

Designed for Long-Term Retrieval

The AVEIR VR LP's predicate device has an overall long-term retrieval success rate above 88% with helix fixation with up to 9 years of retrieval experience.2,3 AVEIR VR LP is designed for long-term retrieval.1  Limited data is available for AVEIR VR LP.

The AVEIR VR LP's predicate device has an overall long-term retrieval success rate of 92.5% for implants ≥ 5 years.3


Long Lasting

Increased projected battery longevity over current available leadless pacemakers2,4* opens the door to more patients.

Mean ± SD: 17.6±6.6 years
95% CI: 16.6 to 18.6 years

Projected years of battery life comparison Aveir VR leadless pacemaker vs Micra leadless pacemaker

The average battery longevity among Leadless II phase 2 IDE patients at 1 year follow-up is estimated to be 17.6 years

48% of the study patients have an estimated battery longevity of over 20 years.5

Up to
Twice the Battery Capacity
of current VR leadless pacemakers2,4*

Aveir VR Leadless Pacemaker battery capacity 243 mAh Micra Leadless Pacemaker  120 mAh

Partnering with You to Personalize Care

Sign up to hear about our technology, education opportunities, and more.

Read the Latest Blog Article

Stay up to date with recent news, product highlights, and case studies.


* Battery longevity estimates based on projections derived from published technical specifications and the ISO standard settings

**For additional information about specific MR Conditional, including warnings, precautions, adverse conditions to MRI scanning and potential adverse events, please refer to the MRI-Ready Leadless Systems Manual at medical.abbott/manuals or check our MRI Ready resources at cardiovascular.abbott/mriready


1. AVEIR DR FDA Approval
2. Aveir™ VR Leadless Pacemaker and Delivery Catheter IFU. ARTEN600175956
3. Reddy, VY, et al. Worldwide Experience with Leadless Pacemaker Retrievals at 9 years. Presented at 15th Asia Pacific Heart Rhythm Society (APHRS) Scientific Session; Nov 18-20, 2022; Singapore.
4. Micra‡ VR IFU M991010A001 REV. B
5. Reddy VY, Exner D, et al. 1-Year Outcomes of a Leadless Ventricular Pacemaker: The LEADLESS II (Phase 2) Trial. JACC : Clinical Electrophysiology 2023, DOI: 10.1016/j.jacep.2023.01.031



a. Sattar et al. Complications of leadless vs conventional (lead) artificial pacemakers - a retrospective review. Journal of community hospital internal medicine perspectives vol. 10,4 328-333. 2 Aug. 2020, doi:10.1080/20009666.2020.178690
b. Reddy VY, Cantillon DJ, John IP. San Francisco, CA: 6 May 2016. A comparative study of acute and mid-term complications of leadless vs transvenous pacemakers. Late-Breaking Clinical Trials II. Presented at Heart Rhythm Society 2016; pp. 02–04. Abstract LBCT.

 Manuals & Resources

Manuals & Resources

Cardiovascular Products

Cardiovascular Products

Reimbursement & Coding

Reimbursement & Coding

MAT-2115643 7.0 | Item is approved for U.S. use only